Literature DB >> 22078870

Altered expression of neuropeptides in the primary somatosensory cortex of the Down syndrome model Ts65Dn.

Samuel Hernández1, Javier Gilabert-Juan, José Miguel Blasco-Ibáñez, Carlos Crespo, Juan Nácher, Emilio Varea.   

Abstract

Down syndrome is the most common genetic disorder associated with mental retardation. Subjects and mice models for Down syndrome (such as Ts65Dn) show defects in the formation of neuronal networks in both the hippocampus and the cerebral cortex. The principal neurons display alterations in the morphology, density and distribution of dendritic spines in the cortex as well as in the hippocampus. Several evidences point to the possibility that the atrophy observed in principal neurons could be mediated by changes in their inhibitory inputs and, in fact, an imbalance between excitation and inhibition has been observed in Ts65Dn mice in these regions, which are crucial for learning and information processing. These animals have an increased density of interneurons in the primary somatosensory cortex, especially of those expressing calretinin and calbindin D-28k. Here, we have analysed the expression and distribution of several neuropeptides in the primary somatosensory cortex of Ts65Dn mice in order to investigate whether these subpopulations of interneurons are affected. We have observed an increase in the total density of somatostatin expressing interneurons and of those expressing VIP in layer IV in Ts65Dn mice. The typology of the somatostatin and VIP interneurons was unaltered as attested by the pattern of co-expression with other markers. Somatostatin immunoreactive neurons co-express mainly D-28k calbindin and VIP expressing interneurons maintain its pattern of co-expression with calcium binding proteins. These alterations, in case they were also present in subjects with Down syndrome, could be related to their impairment in cognitive profile and could be involved in the neurological defects observed in this disorder.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22078870     DOI: 10.1016/j.npep.2011.10.002

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  7 in total

1.  Altered distribution of hippocampal interneurons in the murine Down Syndrome model Ts65Dn.

Authors:  Samuel Hernández-González; Raúl Ballestín; Rosa López-Hidalgo; Javier Gilabert-Juan; José Miguel Blasco-Ibáñez; Carlos Crespo; Juan Nácher; Emilio Varea
Journal:  Neurochem Res       Date:  2014-11-16       Impact factor: 3.996

2.  Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease.

Authors:  Brian Spencer; Rewati Potkar; Jeff Metcalf; Ivy Thrin; Anthony Adame; Edward Rockenstein; Eliezer Masliah
Journal:  J Biol Chem       Date:  2015-11-30       Impact factor: 5.157

Review 3.  The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.

Authors:  Andrea Contestabile; Salvatore Magara; Laura Cancedda
Journal:  Front Cell Neurosci       Date:  2017-03-07       Impact factor: 5.505

4.  Dynamic Causal Modeling of the Relationship between Cognition and Theta-alpha Oscillations in Adults with Down Syndrome.

Authors:  Sarah Hamburg; Richard Rosch; Carla Marie Startin; Karl John Friston; André Strydom
Journal:  Cereb Cortex       Date:  2019-05-01       Impact factor: 5.357

5.  Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome.

Authors:  Martina Kirstein; Alba Cambrils; Ana Segarra; Ana Melero; Emilio Varea
Journal:  Neurochem Res       Date:  2022-06-29       Impact factor: 4.414

Review 6.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

7.  Hypocellularity in the Murine Model for Down Syndrome Ts65Dn Is Not Affected by Adult Neurogenesis.

Authors:  Rosa López-Hidalgo; Raul Ballestín; Jessica Vega; José M Blasco-Ibáñez; Carlos Crespo; Javier Gilabert-Juan; Juan Nácher; Emilio Varea
Journal:  Front Neurosci       Date:  2016-03-02       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.